Apolipoprotein B and LDL-cholesterol: Which parameter(s) should be routinely assayed to assess coronary artery disease?;Apolipoproteine B et cholesterol des LDL: quel(s) parametre(s) inclure dans l'appreciation du risque cardiovasculaire?

Annales de Biologie Clinique

Volumn 56, Issue 5, 1998, Pages 539-544

  Bloch, S ^a   Couderc, R ^a  

^a HÔPITAL TENON   (France)

Author keywords

Apolipoprotein B; Coronary artery disease risk; LDL cholesterol; Plasma lipid profile

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE MARKER; PREDICTION; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; MALE; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR;

APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0032161448     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Couderc R, Legrand A. Bilan lipidique en pratique médicale courante. Biologiste et praticien 1996 : 1-75.
2. Sheperd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 ; 333 : 1301-7.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 ; 344 : 1383-9.
4. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoprotcins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994 ; 120 : 1012-25.
5. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992 ; 69 : 1251-4.
6. Wald NJ, Law M, Watt CH, et al. Apolipoproteins and ischaemic heart disease : implications tor screening. Lancet 1994 ; 343 : 75-9.
7. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996 ; 94 : 273-8.
8. Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk. Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5 790 men. Atherosclerosis 1997 ; 129 : 221-30.
9. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and others risk factors : results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994 ; 24 : 444-53.
10. Campbell AJ, Bushy WJ, Robertson MC. Over 80 years and no evidence of coronary heart disease : characteristics of a survivor group. J Am Geriatr Soc 1993 ; 41 : 1333-8.
11. Kwiterovich PO, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992 ; 69 : 1015-21.
12. Kwiterovich PO, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤ 50 years) and women (≤ 60 years) with coronary artery disease. Am J Cardiol 1993 ; 71 : 631-9.
13. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterol, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb 1994 ; 14 : 1098-104.
14. McGill DA, Talsma P, Ardlie NG. Relationship of blood cholesterol and apoprotein B levels to angiographically defined coronary artery disease in young males. Coronary Artery Disease 1993 ; 4 : 261-70.
15. Kuyl JM, Mendelsohn D. Observed relationship between ratios HDL/Total cholesterol and apolipoprotein A1/Apolipoprotein B. Clin Biochem 1992 ; 25 : 313-6.
16. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Sudy. J Lipid Res 1994 ; 35 : 871-82.
17. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994 ; 35 : 779-92.
18. Wilcken DE, Wang XL, Dudman NP. The apo A. B. a of coronary-risk : back to kindergarten. Aust NZ J Med 1992 ; 22 : 570-5.
19. Beigel Y, George J, Leibovici L, Mattityahu A, Sclarovsky S, Blieden L. Coronary risk factors in children of parents with premature coronary artery disease. Acta Pediatr 1993 ; 82 : 162-5.
20. Wilcken DE, Xing Li Wang MB, Greenwood J, Lynch J. Lipoprotein (a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents. J Pediatr 1993 ; 123 : 519-26.
21. Widhalm K, Koch S, Pakosta R, Schurz M, Brendinger M. Serum lipids, Lipoproteins and Apoliproteins in children with and without familial history of premature coronary heart disease. J Am Coll Nutr 1992 ; 11 : 32S-5.
22. Srinivasan SR, Berenson GS. Serum apolipoproteins A-1 and B as markers of coronary artery disease risk in early life : the Bogalusa heart study. Clin Chem 1995 ; 41 : 159-64.
23. Rosseneu M, Fruchart JC, Bard JM, et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS study. Circulation 1994 ; 89 : 1967-73.
24. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals, for plasma apolipoprotein B determined with a standardised commercial immunoturbidimetric assay : results from the Framingham Offspring Study. Clin Chem 1996 ; 42 : 4515-23.
25. 2* method. Clin Chem 1997 ; 43 : 816-23.
26. Reed RG. In search of the ideal measure of high-density lipoprotein. Clin Chem 1997 ; 3 : 1809-10.
27. Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of non chylomicronemic dyslipemia. Clin Chem 1997 ; 43 : 5808-151.
28. Salonen JT, Salonen R, Penttilä I, et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 1985 ; 56 : 226-31.
29. Stampfer M, Sacks F, Salvini S, Willett W, Hennekens C. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991 ; 325 : 373-81.
30. Coleman MP, Wang DY, Hermon C, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992 ; 92 : 177-85.